Since 2012, the number of reported cases of invasive serogroup C meningococcal (IMI C) infections has been increasing in the wider Paris region (Ile-de-France), as in the rest of the country. Adults aged between 25 and 49 years and those aged 50 years or over are concerned, mainly men and notably those who have sex with men (MSM) in whom a specific variant of meningococcus C circulates.
The HCSP reminds that the protection of adults over 24 years of age relies on achieving a high vaccination coverage in the age group targeted in the immunisation schedule (1 to 24 years) The latter is grossly insufficient in adolescents and young adults.
The HCSP recommends meningococcal C conjugate vaccination for MSM, as well as for anyone over the age of 25 who frequents gay meeting places and social scenes.
Considering the foreseeable shortage of monovalent meningococcal C conjugate vaccine doses, the HCSP recommends the use of one of the tetravalent ACWY conjugate vaccines to vaccinate the adults concerned by this notice. The use of this vaccine in persons likely to travel offers the benefit of a wider protection. A long-term protection against serogroup C meningococcal infections is also expected with this type of vaccine in this category of population.
The recommended immunisation schedule corresponds to that of the marketing authorisations of the meningococcal conjugate vaccines and includes a single vaccine dose.
- Recommendation
- Europe
- France
- Meningococcal disease
